Hikma Pharmaceuticals PLC (#HIK) Stock Price, Live Chart & Analysis | Trade #HIK
Hikma Pharmaceuticals is a British pharmaceutical company headquartered in London and operating in most of the regions of the world. Hikma Pharmaceuticals manufactures injectables, generics and branded products. The company's products are used for treating infections, cardiovascular diseases, cancer, diabetes, nervous system diseases etc. Hikma Pharmaceuticals products can be found both in healthcare institutions and in retail markets around the world.
The company acquires new companies in various regions of the planet, concludes agreements with other pharmaceutical companies and expands its operations. In 2021, the company acquired the US-based Custopharm which expanded its presence in the injectables market and led to an increase in the HIK stock price. The HIK rate is influenced by the company's financial statements. Good performance may lead to the HIK price increase.
When trading Hikma Pharmaceuticals stock, traders should follow the industry news. New diseases emerging around the world require medication to prevent and treat them. There is very high competition in the pharmaceutical industry. Even small companies and startups are sometimes able to occupy free market niches. If Hikma Pharmaceuticals comes up with a new medication first, the HIK stock price will increase.
Risk warning: Trading in FX and CFDs entails high risk of losing capital.
Are you interested in buying Hikma Pharmaceuticals PLC (#HIK)? It’s easy!
SellBuyActive SellActive Buy
| Sell | 1996 |
| Buy | 1999 |
| 1-day change | 105(5.55%) |
Earn from the fluctuations of prices and boost your income with LiteFinance!
Price chart of #HIK in real time mode
Available in trading accounts:
- ECN
- CLASSIC
Prev. Close1,993
Day's Range1.0000 - 2.0000
Opening2,002
52 wk Range1,711-2,193
Volume699,329
Shares Outstanding221,747,575
Average Volume353,342
Market Cap4.4B
1-Year Return-8.74%
EPS1.29
Beta0.396
Revenue3.02B
P/E Ratio20.39
Dividends0.79(3.04%)
Next Earnings Daten/a
Spread0
Swap Long-6
Contract size1
Swap Short2.5
Stop&Limit Level0
| #AHT | N/A | N/A | -202 | -3.60% |
| #BAES | N/A | N/A | 80 | 6.23% |
| #BARC | N/A | N/A | -9.75 | -4.11% |
| #BATS | N/A | N/A | 73 | 2.64% |
| #BLND | N/A | N/A | 3.8 | 0.94% |
| #BRBY | N/A | N/A | -99 | -12.87% |
| #BT | N/A | N/A | -1.65 | -1.17% |
| #HIK | N/A | N/A | 105 | 5.55% |
| #HSBA | N/A | N/A | -30.5 | -4.39% |
| #III | N/A | N/A | 62 | 2.00% |
| #IMB | N/A | N/A | 26 | 1.21% |
| #ITRK | N/A | N/A | -81 | -1.62% |
| #NWG | N/A | N/A | -21 | -5.72% |
| #PSON | N/A | N/A | -9 | -0.85% |
| #TSCO | N/A | N/A | 21 | 6.33% |
| #UU | N/A | N/A | -7.5 | -0.73% |
| #VOD | N/A | N/A | 1.86 | 2.58% |
Interesting facts about the #HIK (Hikma Pharmaceuticals PLC)
Headquartered in London, Hikma Pharmaceuticals was founded in Jordan in 1978. In the 1980s, the company managed to launch the first FDA-regulated manufacturing plant in the MENA region. Later that decade, Hikma founded a sterile manufacturing plant in Portugal, spreading its business beyond the Middle East. In the 1990s, the firm entered the American, Tunisian, and Saudi Arabian markets through several acquisitions. In the 2000s, Hikma Pharmaceuticals continued expanding, making acquisitions in Italy, Germany, and Egypt. In the 2010s, it entered Algerian and Moroccan markets and made more acquisitions in the US.
The corporation went public in 2005 via a listing on the London Stock Exchange under the ticker symbol "HIK." Also, Hikma has an American Depositary Receipt listed on OTC under the ticker "HKMPY." One ADR equals two ordinary shares. Global Depositary Receipts of the firm are listed on NASDAQ Dubai under EPIC – HIK. Currently, the company’s shares are included in several stock indices. The most popular ones are FTSE 100, FTSE 350, and STOXX 600. An inclusion in the global index confirms the reliability of the corporation.
Although its stock price is low, Hikma Pharmaceuticals Plc is an attractive investment. The company pays dividends twice a year. The dividend payments grow progressively. Hikma Pharmaceuticals has a good cash flow generation and a low leverage of net debt/EBITDA.
If you aren’t sure about the effectiveness of investments, you can use CFD trading. Being a pharmaceutical company, Hikma Pharmaceuticals is involved in scandals and lawsuits. However, they rarely, in fact, occur. Usually, court cases are related to workplace safety or health violations and false claims. When trading shares, pay attention to ongoing cases as they can lead to significant penalties.
Although Hikma is famous for a large number of acquisitions, it has competitors. Its key rivals are Pierre Fabre, Teva, Perrigo, and Takeda. HIK stock price can be negatively affected if any of these companies outperform Hikma.
Hikma has a positive net impact ratio due to its positive influence on physical diseases, jobs and taxes. A positive net impact ratio always attracts investors and traders.
Follow us in social networks!
Live Chat
Leave a feedback